Navigation Links
AVANIR Pharmaceuticals To participate in two conferences in March
Date:3/1/2013

ALISO VIEJO, Calif., March 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

  • Cowen & Company 33rd Annual Healthcare Conference
    • Location: Boston Marriott Copley Place, Boston, MA
    • Presentation date: Tuesday March 5, 2013
    • Presentation time: 9:20 a.m. E.T.
  • 25th Annual ROTH Conference
    • Location: Ritz-Carlton, Laguna Niguel, CA
    • Presentation date: Wednesday March 20, 2013
    • Presentation time: 11:30 a.m. P.T.

A live webcast and 30-day archive of these presentations will be available at http://ir.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
2. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 With the accelerated ... personal health expenditure as well as the improved ... China diagnostic reagent industry has been developing quickly, ... In 2013, Chinese in vitro diagnostics market size ... from in vitro diagnostic reagents. , Read ...
(Date:7/30/2014)... Yuma Regional Cancer Center Officially Opens ... comprehensive cancer care to Yuma, Arizona. , The ... has officially opened. A Mayo Clinic Care Network ... as open, semi-private and private infusion rooms, oncology ... Center, hematology, rehabilitation center, a pain management program ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Connecticut Center ... organization based in East Hartford, Conn., was awarded a ... II of a project that will determine the feasibility ... rural north-central Connecticut. USDA Rural Development provided $53,000 for ... for the second phase of the feasibility study in ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... Enlarge and Worsen Over Time , , CHICAGO, June 15 ... enlarged leg veins as a cosmetic issue without recognizing they can ... their doctors for other health symptoms, Vein Clinics of America is ... from affecting their everyday routine. , , To view the ...
... 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... appointment of Scott Peterson, Ph.D., as Vice President, ... Dr. Peterson will be responsible for overseeing those ... will support the advancement of the Company,s pipeline ...
... June 15 Congressional Quarterly presents a 360-degree look ... follow-on versions of biotech drugs. This CQ Forum will ... groups, and leading researchers regarding the complex structures of ... Will the availability of these products save money for ...
Cached Biology Technology:Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 2Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 3Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 4Oncothyreon appoints Scott Peterson as Vice President of Research and Development 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 3
(Date:7/30/2014)... is a subject of major interest in neuroscience. ... during the distinct stages of Wallerian degeneration: transcription ... dedifferentiation. Although gene expression responses in the distal ... injury are known, differences in gene expression between ... Dengbing Yao and co-workers from Nantong University, China ...
(Date:7/30/2014)... multitude of cells types. Researchers would like to understand how ... cells that make up the organs and other structures of ... chains of sugars that dangle from proteins on surfaces of ... San Diego, has created synthetic molecules that can stand in ... to direct the process, they report in the Journal ...
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... to John Ellis for his pioneering contributions to biochemistry, ... Professor in the Department of Biological Sciences at the ... of the Springer book How Science Works: Evolution. Dr. ... London, and completed postdoctoral studies at Oxford University. In ...
... centuries-old religious ceremony of an indigenous people in southern Mexico ... of fish, according to researchers from Texas A&M University. ... World, the Zoque people of southern Mexico would venture each ... Cueva del Azufre to implore their deities for a bountiful ...
... most frustrating problems faced by doctors who treat pancreatic cancer ... 38,000 people in the United States die of the disease ... For almost three decades, scientists and physicians have known ... virtually all pancreatic cancers, making it an important target for ...
Cached Biology News:Moved by religion: Mexican cavefish develop resistance to toxin 2Moved by religion: Mexican cavefish develop resistance to toxin 3UNC team discovers promising target for new pancreatic cancer treatments 2
Request Info...
Polyclonal Antibody to CLAN...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: